Your browser doesn't support javascript.
loading
Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings.
Keyserling, Constance H; Barbaras, Ronald; Benghozi, Renee; Dasseux, Jean-Louis.
Affiliation
  • Keyserling CH; Cerenis Therapeutics, 265 rue de la Découverte-Bât. A, 31670, Labège, France. Keyserling@cerenis.com.
  • Barbaras R; Cerenis Therapeutics, 265 rue de la Découverte-Bât. A, 31670, Labège, France.
  • Benghozi R; Cerenis Therapeutics, 265 rue de la Découverte-Bât. A, 31670, Labège, France.
  • Dasseux JL; Cerenis Therapeutics, 265 rue de la Découverte-Bât. A, 31670, Labège, France.
Clin Drug Investig ; 37(5): 483-491, 2017 May.
Article in En | MEDLINE | ID: mdl-28213743
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phospholipids / Recombinant Proteins / Cholesterol / Apolipoprotein A-I Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Adult / Animals / Female / Humans / Male / Middle aged Language: En Journal: Clin Drug Investig Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2017 Document type: Article Affiliation country: France Country of publication: New Zealand
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phospholipids / Recombinant Proteins / Cholesterol / Apolipoprotein A-I Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Adult / Animals / Female / Humans / Male / Middle aged Language: En Journal: Clin Drug Investig Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2017 Document type: Article Affiliation country: France Country of publication: New Zealand